Correction: Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up
Ryosuke Sato, Katsuyuki Hotta, Toshio Kubo, Shigeru Horiguchi, Hironari Kato, Kazuyuki Matsumoto, Toshiyuki Kozuki, Heiichiro Udono, Katsuyuki Kiura, Motoyuki Otsuka
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPancreatic and Hepatic Oncology Research · Cancer Immunotherapy and Biomarkers · Colorectal Cancer Treatments and Studies
This article has been corrected to include previously omitted conflicts of interest:
1) Financial Relationships: The statement "All authors have declared that no financial support was received from any organization for the submitted work" has been corrected as follows: "The research funding and investigational agent (nivolumab) were provided by Ono Pharmaceutical Co., Ltd."
2) Payment/services info: The statement "All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work." has been corrected as follows:
"Katsuyuki Hotta reports honoraria from AZ, Chugai, Lilly, MSD, BMS, Ono, Boehringer-Ingelheim, Nippon Kayaku, Amgen, Taiho, Merck, Janssen, and Takeda, and grants from MSD, AZ, Lilly, BMS, Abbvie, and Janssen, outside the submitted work.
Toshio Kubo reports honoraria from Chugai outside the submitted work.
Toshiyuki Kozuki reports honoraria from from Chugai, AZ, Lilly, Taiho, BMS, Ono, MSD, Pfizer, Nippon Beohringer Ingelheim, Merck Biophama, Nippon Kayaku, Novartis, Daiichi-Sankyo, Takeda Pharmaceutical, Bayer, AMGEN, Janssen, Eisai, Kyorin, and Otsuka Pharmaceutical, and grants from AZ, Chugai, Lilly, Taiho, BMS, Ono, MSD, Kyowa Hakko Kirin, Merck Biopharma, Daiichi-Sankyo, AMGEN, Abbvie, Sanofi, Eisai, Labcorp Development Japan, IQVIA Services Japan, Giliead Sciences, Pfizer, and Bayer, outside the submitted work. He also reports consulting fees from Chugai, AZ, Ono, Pfizer, Daiichi-Sankyo, Bayer, Abbvie, Nippon Beohringer Ingelheim, Regeneron, and GSK, outside the submitted work.
Other authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work."